
Evelyne provides advice and counsel on issues relating to US and international laws and regulations concerning intellectual property. She has experience with patent, trademark, and copyright issues and has worked on complex IP transactions involving patent licensing and IP asset acquisition.
Evelyne has also conducted due diligence evaluations of patents, patent oppositions, patent litigation, and patent interference proceedings, and she has prepared documents for proceedings before the Board of Patent Appeals and Interferences and the Federal Circuit. In addition, she has drafted intellectual property agreements, stock purchase agreements, confidentiality agreements, conflict of interest policy, memoranda of understanding, independent contractor agreements, and patent applications.
Prior to joining Mintz, Evelyne served as an in-house attorney at a start-up company, a senior scientific/legal analyst for an international law firm, and as in-house counsel for KPMG – FIDAL and Fiduciaire de France. She speaks French, Italian, and English.
News & Press
Mintz Advises Underwriters in Assembly Biosciences' $175 Million Underwritten Offering and Concurrent Private Placement
August 18, 2025
Mintz advised the underwriters in connection with Assembly Biosciences, Inc.’s underwritten offering of an aggregate of 5,591,840 shares of common stock and pre-funded warrants to purchase up to 1,040,820 shares of common stock, together with accompanying Class A and Class B warrants to purchase up to an aggregate of 6,632,660 shares of common stock at a combined price per share of common stock and accompanying Class A warrant and Class B warrant of $19.60 and a combined price per pre-funded warrant and accompanying Class A warrant and Class B warrant of $19.599.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Mintz Advises Underwriters of Viking’s $287.5 Million Public Offering of Common Stock
April 10, 2023
NEW YORK – Mintz represented the syndicate of underwriters led by William Blair & Company, L.L.C., in the public offering of 17,242,000 shares of common stock of Viking Therapeutics, Inc. (“Viking”) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, at an initial offering price of $14.50 per share.
